[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Harrow Inc. (NASDAQ: HROW) reports first-quarter 2026 earnings after the close on Monday, May 11, with analysts projecting a loss of $0.43 per share on revenue of approximately $52.4 million. The ophthalmic pharmaceutical company faces a critical test as Wall Street watches whether recent operational momentum can offset margin pressures and elevated expectations following a volatile earnings track record. With shares trading at $38.23—well below the $66.71 analyst price target—the report will determine if HROW can validate its growth narrative or if mounting skepticism is warranted.

Harrow Inc. is a commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics, focusing on proprietary, generic, and...

Fundamentals

See More
  • Market Capitalization, $K 1,424,946
  • Shares Outstanding, K 37,273
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ 31 M
  • EBITDA $ 54 M
  • 60-Month Beta 0.34
  • Price/Sales 5.35
  • Price/Cash Flow 45.18
  • Price/Book 27.76

Options Overview Details

View History
  • Implied Volatility 78.81% (+2.51%)
  • Historical Volatility 40.24%
  • IV Percentile 61%
  • IV Rank 47.85%
  • IV High 110.75% on 08/07/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 5) 4.77 (12.47%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 577
  • Volume Avg (30-Day) 792
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 42,475
  • Open Int (30-Day) 41,339
  • Expected Range 33.46 to 43.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.43
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.69
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.50 +7.68%
on 04/10/26
42.13 -9.26%
on 04/17/26
+1.50 (+4.08%)
since 04/08/26
3-Month
33.03 +15.76%
on 03/23/26
54.49 -29.84%
on 02/26/26
-9.09 (-19.21%)
since 02/06/26
52-Week
21.12 +81.01%
on 05/09/25
54.85 -30.30%
on 01/07/26
+14.64 (+62.06%)
since 05/08/25

Most Recent Stories

More News
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 38.23 (-2.10%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 38.23 (-2.10%)
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 38.23 (-2.10%)
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE ® 1% (apraclonidine...

HROW : 38.23 (-2.10%)
LogiCare3PL Selected as Distribution Partner by Harrow

OLIVE BRANCH, Miss. , April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic...

HROW : 38.23 (-2.10%)
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private...

HROW : 38.23 (-2.10%)
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer,...

HROW : 38.23 (-2.10%)
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts...

HROW : 38.23 (-2.10%)
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 38.23 (-2.10%)
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug...

HROW : 38.23 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 40.24
2nd Resistance Point 39.76
1st Resistance Point 39.00
Last Price 38.23
1st Support Level 37.76
2nd Support Level 37.28
3rd Support Level 36.52

See More

52-Week High 54.85
Fibonacci 61.8% 41.97
Last Price 38.23
Fibonacci 50% 37.99
Fibonacci 38.2% 34.00
52-Week Low 21.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.